A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: The SEZE trial

被引:7
作者
Chung, Woo-Young [2 ]
Kang, Jeehoon [3 ]
Cho, Young-Seok [1 ]
Park, Hae-Jun
Yang, Han-Mo [3 ]
Seo, Jae-Bin [2 ]
Sub, Jung-Won
Kim, Kwang-Il
Youn, Tae-Jin
Kim, Sang-Hyun [2 ]
Chae, In-Ho
Zo, Joo-Hee [2 ]
Kim, Myung-A [2 ]
Choi, Dong-Ju
机构
[1] Seoul Natl Univ, Bundang Hosp, Cardiovasc Ctr, Songnam 463707, Gyeonggi, South Korea
[2] Seoul Natl Univ, Boramae Hosp, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Seoul 110744, South Korea
关键词
sirolimus-eluting stent; zotarolimus-eluting stent; ST elevation myocardial infarction; late lumen loss; CORONARY-ARTERY-DISEASE; INTRAVASCULAR ULTRASOUND ANALYSIS; BARE-METAL STENTS; FOLLOW-UP; NEOINTIMAL HYPERPLASIA; CLINICAL-OUTCOMES; UNCOATED STENTS; IMPLANTATION; LESIONS; THROMBOSIS;
D O I
10.3760/cma.j.issn.0366-6999.2012.19.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The zotarolimus-eluting stent has shown larger in-stent late lumen loss compared to sirolimus-eluting stents in previous studies. However, this has not been thoroughly evaluated in ST elevation myocardial infarction. Methods This was a prospective, randomized, controlled trial evaluating angiographic outcomes in patients presenting with ST elevation myocardial infarction, treated with zotarolimus-eluting stents or sirolimus-eluting stents. From March 2007 to February 2009, 122 patients were randomized to zotarolimus-eluting stents or sirolimus-eluting stents in a 1:1 fashion. The primary endpoint was 9-month in-stent late lumen loss confirmed by coronary angiography, and secondary endpoints were percent diameter stenosis, binary restenosis rate, major adverse cardiac events (a composite of cardiac death, non-fatal myocardial infarction, and target vessel revascularization), and late-acquired incomplete stent apposition. Results Angiographic in-stent late lumen loss was significantly higher in the zotarolimus-eluting stent group compared to the sirolimus-eluting stent group ((0.49 +/- 0.65) mm vs. (0.10 +/- 0.46) mm, P=0.001). Percent diameter stenosis at 9-month follow-up was also larger in the zotarolimus-eluting stent group ((30.0 +/- 17.9)% vs. (17.6 +/- 14.0)%, P<0.001). In-segment analysis showed similar findings. There were no significant differences in binary restenosis rate, major adverse cardiac events, and late-acquired incomplete stent apposition. Conclusions Compared to sirolimus-eluting stents, the zotarolimus-eluting stent is associated with significantly higher in-stent late lumen loss at 9-month angiographic follow-up in the treatment of ST elevation myocardial infarction. Although there was no significant difference in 1-year clinical outcomes, the clinical implication of increased late lumen loss should be further studied. Chin Med J 2012;125(19):3373-3381
引用
收藏
页码:3373 / 3381
页数:9
相关论文
共 52 条
[1]   Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent [J].
Abizaid, Alexandre ;
Lansky, Alexandra J. ;
Fitzgerald, Peter J. ;
Tanajura, Luis Fernando ;
Feres, Fausto ;
Staico, Rodolfo ;
Mattos, Luiz ;
Abizaid, Andrea ;
Chaves, Aurea ;
Centemero, Marinella ;
Sousa, Amanda G. M. R. ;
Sousa, J. Eduardo ;
Zaugg, Margo J. ;
Schwartz, Lewis B. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (10) :1403-1408
[2]   Late incomplete stent apposition after sirolimus-eluting stent implantation - A serial intravascular ultrasound analysis [J].
Ako, J ;
Morino, Y ;
Honda, Y ;
Hassan, A ;
Sonoda, S ;
Yock, PG ;
Leon, MB ;
Moses, JW ;
Bonneau, HN ;
Fitzgerald, PJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (06) :1002-1005
[3]  
Aoki J, 2005, CIRCULATION, V112, P3876
[4]   Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials [J].
Bavry, Anthony A. ;
Kumbhani, Dharam J. ;
Helton, Thomas J. ;
Borek, Przemyslaw P. ;
Mood, Girish R. ;
Bhatt, Deepak L. .
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (12) :1056-1061
[5]   Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions [J].
Colombo, A ;
Drzewiecki, J ;
Banning, A ;
Grube, E ;
Hauptmann, K ;
Silber, S ;
Dudek, D ;
Fort, S ;
Schiele, F ;
Zmudka, K ;
Guagliumi, G ;
Russell, ME .
CIRCULATION, 2003, 108 (07) :788-794
[6]   Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis [J].
Cook, Stephane ;
Ladich, Elena ;
Nakazawa, Gaku ;
Eshtehardi, Parham ;
Neidhart, Michel ;
Vogel, Rolf ;
Togni, Mario ;
Wenaweser, Peter ;
Billinger, Michael ;
Seiler, Christian ;
Gay, Steffen ;
Meier, Bernhard ;
Pichler, Werner J. ;
Jueni, Peter ;
Virmani, Renu ;
Windecker, Stephan .
CIRCULATION, 2009, 120 (05) :391-399
[7]   Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials [J].
Cutlip, DE ;
Chauhan, MS ;
Baim, DS ;
Ho, KKL ;
Popma, JJ ;
Carrozza, JP ;
Cohen, DJ ;
Kuntz, RE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (12) :2082-2089
[8]   Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation - Analysis from the TAXUS-IV trial [J].
Ellis, SG ;
Popma, JJ ;
Lasala, JM ;
Koglin, JJ ;
Cox, DA ;
Hermiller, J ;
O'Shaughnessy, C ;
Mann, JT ;
Turco, M ;
Caputo, R ;
Bergin, P ;
Greenberg, J ;
Stone, GW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (08) :1193-1200
[9]   Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine encapsulated stent for treatment of native coronary artery lesions:: Clinical and angiographic results of the ENDEAVOR II trial [J].
Fajadet, Jean ;
Wijns, William ;
Laarman, Gert-Jan ;
Kuck, Karl-Heinz ;
Ormiston, John ;
Munzel, Thomas ;
Popma, Jeffrey J. ;
Fitzgerald, Peter J. ;
Bonan, Raoul ;
Kuntz, Richard E. .
CIRCULATION, 2006, 114 (08) :798-806
[10]   CORONARY PLAQUE DISRUPTION [J].
FALK, E ;
SHAH, PK ;
FUSTER, V .
CIRCULATION, 1995, 92 (03) :657-671